Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.73 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.73 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.73 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.73 |
| ▸ | PRKDC | P78527 | 2/20 | 0.73 |
| ▸ | SRC | P12931 | 11/20 | 0.64 |
| ▸ | ABL1 | P00519 | 6/20 | 0.64 |
| ▸ | RET | P07949 | 6/20 | 0.63 |
| ▸ | KDR | P35968 | 5/20 | 0.63 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.60 |
| ▸ | PRKD2 | Q9BZL6 | 4/20 | 0.60 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.60 |
| ▸ | FYN | P06241 | 3/20 | 0.60 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.60 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.60 |
| ▸ | CSK | P41240 | 2/20 | 0.60 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.60 |
| ▸ | CDK2 | P24941 | 1/20 | 0.60 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.60 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL130720 | 0.85 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL27953710 | 0.80 | PIK3CD (0.70) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL1964558 | 0.78 | SRC (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL29390060 | 0.78 | SRC (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL29390926 | 0.78 | SRC (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL19463771 | 0.77 | RET (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL6055053 | 0.77 | SRC (0.64) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL22275942 | 0.77 | PIK3CD (0.69) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL409031 | 0.76 | SRC (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL173288 | 0.75 | SRC (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512125-B2 | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512125-B2 | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-12-06 | — | — | US | disclosed |
| US-20110144134-A1 | Anti-Inflammatory Pyrazolopyrimndines | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144134-A1 | Anti-Inflammatory Pyrazolopyrimndines | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-06-16 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100273776-A1 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRx PHARMACEUTICALS, INC (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273776-A1 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRx PHARMACEUTICALS, INC (US) | 2010-10-28 | — | — | US | disclosed |
| US-20090124638-A1 | ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124638-A1 | ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2007126841-A2 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | FOLDRX PHARMACEUTICALS, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273776-A1 | INHIBITION OF ALPHA-SYNUCLEIN TOXICITY | SNCA, PARK7, PINK1 | PIK3CD 3362/4885PIK3CA 4331/4885PIK3CB 2493/4885 |
| US-20110144134-A1 | Anti-Inflammatory Pyrazolopyrimndines | TSLP, NLRP3, IL1B | PIK3CD 3674/4885PIK3CA 3812/4885PIK3CB 3559/4885 |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | PIK3CD 2217/4885PIK3CA 3103/4885PIK3CB 1964/4885 |
| US-20090124638-A1 | ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES | TNF, TSLP, IL1B | PIK3CD 3413/4885PIK3CA 2924/4885PIK3CB 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.